Uterine cancer incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of uterine cancer, 2015-2017, UK

 

Proportion of all cases

Percentage uterine cancer is of total cancer cases, 2015-2017, UK

 

Age

Peak rate of uterine cancer cases, 2015-2017, UK

Trend over time

Change in uterine cancer incidence rates since the early 1990s, Females, UK

 

Uterine cancer is the 4th most common cancer in females in the UK, accounting for 5% of all new cancer cases in females (2017).

In females and males combined, uterine cancer is the 13th most common cancer in the UK, accounting for 3% of all new cancer cases (2017).[1-4]

Uterine cancer incidence rates (European age-standardised (AS) rates Open a glossary item) are similar to the UK average in all the UK constituent countries.

Uterine Cancer (C54-C55), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, Females, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Cases 7,862 850 520 262 9,494
Crude Rate 27.9 30.5 32.8 27.6 28.4
AS Rate 28.9 29.8 30.8 30.2 29.1
AS Rate - 95% LCL 28.2 27.8 28.1 26.5 28.5
AS Rate - 95% UCL 29.5 31.8 33.4 33.8 29.6
Persons Cases 7,862 850 520 262 9,494
Crude Rate 14.1 15.7 16.6 14.0 14.4
AS Rate 15.2 15.9 16.1 16.0 15.3
AS Rate - 95% LCL 14.8 14.8 14.8 14.0 15.0
AS Rate - 95% UCL 15.5 17.0 17.5 17.9 15.6

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item  around the AS Rate Open a glossary item

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, August 2018. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2018. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, February 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, April 2018. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C54-C55.

Last reviewed:

Uterine cancer incidence is related to age, with the highest incidence rates being in older women. In the UK in 2015-2017, on average each year more than a quarter of new cases (27%) were in females aged 75 and over.[1-4]

Age-specific incidence rates rise steeply from around age 45-49 before dropping in the oldest age groups - a slighly different pattern from most cancers.The highest rates are in in the 75 to 79 age group.

Uterine cancer (C54-C55), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Females, UK, 2015-2017

For uterine cancer, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

The age distribution of uterine cancer cases probably reflects hormonal changes during and after the menopause.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, C54-C55.

Last reviewed:

Uterine cancer European age-standardised (AS) incidence rates for females increased by 55% in the UK between 1993-1995 and 2015-2017.[1-4].

Over the last decade in the UK (between 2005-2007 and 2015-2017), uterine cancer AS incidence rates for females increased by 13%.[1-4]

Uterine Cancer (ICD-10 C54-C55), European Age-Standardised Incidence Rates, Females, UK, 1993-2017

Uterine cancer incidence rates have increased overall in most broad adult age groups in females in the UK since the early 1990s, but have remained stable in others.[1-4] Rates in 0-24s have remained stable, in 25-49s have increased by 36%, in 50-59s have increased by 33%, in 60-69s have increased by 59%, in 70-79s have increased by 85%, and in 80+s have increased by 45%.

Uterine Cancer (ICD-10 C54-C55), European Age-Standardised Incidence Rates, By Age, Females, UK, 1993-2017

For uterine cancer, like most cancer types, incidence trends largely reflect changing prevalence of risk factors and improvements in diagnosis and data recording. Recent incidence trends are influenced by risk factor prevalence in years past, and trends by age group reflect risk factor exposure in birth cohorts.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1993-2017, ICD-10 C54-C55.

Last reviewed:

Overall stage at diagnosis

A high proportion (89-93%) of uterine cancer cases in England and Northern Ireland have stage at diagnosis recorded.[1,2]

Uterine cancer patients with a known stage are most commonly diagnosed at stage I (74-75%). More patients with a known stage are diagnosed at an early stage (81-83% are diagnosed at stage I or II), than a late stage (18-19% are diagnosed at stage III or IV). Between 7% and 8% of uterine cancer patients have metastases at diagnosis (stage IV).[1,2]

The stage distribution for each cancer type will reflect many factors including how the cancer type develops, the way symptoms appear, public awareness of symptoms, how quickly a person goes to see their doctor and how quickly the cancer is recognised and diagnosed by a doctor. It might also relate to whether a national screening programme that can detect early stage disease exists for that cancer type, along with the extent of uptake of that programme.

A cancer type associated with a large proportion of early stage diagnoses could be one that is more likely to be symptomatic at an earlier stage of development, with recognisable symptoms rather than more generic ones.

Uterine Cancer (C54-C55), Proportion of Cases Diagnosed at Each Stage, All Ages, England 2014, Northern Ireland 2010-2014

Data should not be compared between countries due to differences in time periods and possible differences in recording of stage at diagnosis.

Stage at diagnosis by deprivation

Late stage at diagnosis of uterine cancer is not associated with deprivation in England.[3]

Stage at diagnosis by age

Late stage at diagnosis of uterine cancer is more common in adults aged 80+ in England (26% diagnosed at stage III or IV), compared to those aged 60-79 (17% diagnosed at stage III or IV). And younger adults aged 15-59 (13% diagnosed at stage III or IV).[3]

Late stage uterine cancer is also more common in adults aged 60-79 in England (17% diagnosed at stage III or IV) compared to younger adults aged 15-59 (13% diagnosed at stage III or IV).[3]

These patterns by deprivation, age and sex are probably not explained  by other demographic differences.[4]

References

  1. National Cancer Intelligence Network. Stage Breakdown by CCG 2014. London: NCIN; 2016.
  2. Northern Ireland Cancer Registry, Queens University Belfast, Incidence by stage 2010-2014. Belfast: NICR; 2016.
  3. National Cancer Registration and Analysis Service. Routes to diagnosis of cancer by stage 2012-2013 workbook. London: NCRAS; 2016.
  4. Lyratzopoulos G, Abel G, Brown C, et al. Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer. Annals of Oncology, 2012:843-50.

About this data

Data is for: England 2014 ICD-10 C54, Northern Ireland 2010-2014, ICD-10 C54-C55 (overall stage at diagnosis) and England, 2012-2013, ICD-10 C54-C55 (stage at diagnosis by deprivation, age, sex, and ethnicity)

Data is not comparable between countries due to differences in time periods and possible differences in how countries record stage at diagnosis.

The proportions of patients diagnosed late only include cases with a known stage at diagnosis and are not adjusted for other demographics differences (e.g. age, sex, ethnicity) unless stated otherwise.

Last reviewed:

Most uterine cancer cases occur in the endometrium Open a glossary item, with much smaller proportions in the myometrium, fundus uteri and isthmus uteri (2010-2012).[1-4]

A small proportion of cases did not have the specific part of the uterus recorded in cancer registry data, or overlapped more than one part.[1-4]

Cases and percentages may not sum due to rounding

References

  1. Data were provided by the Office for National Statistics on request, July 2014. Similar data can be found here: http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html.
  2. Data were provided by ISD Scotland on request, April 2014. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit on request, April 2014. Similar data can be found here: http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=59080.
  4. Data were provided by the Northern Ireland Cancer Registry on request, June 2014. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/CancerInformation/.

About this data

Data is for: UK, 2010-2012, ICD10- C54-55

Last reviewed:

Uterine cancer incidence rates are projected to fall by 7% in the UK between 2014 and 2035, to 33 cases per 100,000 females by 2035.[1]

Uterine cancer (C54-C55), Observed and Projected Age-Standardised Incidence Rates, by Sex, UK, 1979-2035

 

It is projected that 11,576 cases of uterine cancer will be diagnosed in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C54-C55

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

Uterine cancer incidence rates (European age-standardised (AS) rates Open a glossary item) in England in females are 17% higher in the most deprived quintile compared with the least, and in males are  in the most deprived quintile compared with the least (2013-2017).[1]

It is estimated that there are around 640 more cases of uterine cancer each year in England than there would be if every deprivation quintile had the same age-specific crude incidence rates as the least deprived quintile. 

Uterine Cancer (C54-C55), Estimated Average Number of Excess Cases per Year and European Age-Standardised Incidence Rates per 100,000 Population, by Deprivation Quintile, England, 2013-2017

References

  1. 1.    Calculated by the Cancer Intelligence Team at Cancer Research UK, April 2020. Based on method reported in National Cancer Intelligence Network Cancer by Deprivation in England Incidence, 1996-2010 Mortality, 1997-2011. Using cancer incidence data 2013-2017 (Public Health England) and population data 2013-2017 (Office for National Statistics) by Indices of Multiple Deprivation 2015 income domain quintile, cancer type, sex, and five-year age band.

About this data

Data is for England, 2013-2017, ICD-10 C54-C55.

Last reviewed:

Age-standardised rates Open a glossary item for White females with uterine (womb) cancer range from 16.9 to 17.7 per 100,000. Rates for Asian and Black females are similar ranging from 10.7 to 18.0 per 100,000 and 13.7 to 23.6 per 100,000 respectively.[1] There appears to be no significant variation in uterine (womb) cancer incidence by ethnicity in the UK.

Ranges are given because of the analysis methodology used to account for missing and unknown data. For uterine (womb) cancer, 27,680 cases were identified; 22% had no known ethnicity.

References

  1. National Cancer Intelligence Network and Cancer Research UK. Cancer Incidence and Survival by Major Ethnic Group, England, 2002-2006. 2009.

About this data

Data is for: England, 2002-2006, ICD-10 C54-C55

Last reviewed:

An estimated 70,200 women who had been diagnosed with uterine cancer between 1991 and 2010 were alive in the UK at the end of 2010.[1]

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 C45-C55

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.